8月11日,江苏中慧元通生物科技股份有限公司(简称“中慧生物”,股票代码:2627.HK)正式在中国香港联交所主板挂牌上市,开盘即大涨156%。公司核心产品之一四价流感病毒亚单位疫苗(慧尔康欣®)是国内首款且截至目前唯一获批的四价流感病毒亚单位疫苗。中慧生物成为高特佳投资又一IPO项目。中慧生物董事长、总经理安有才表示:“上市不是终点,而是新的起点。我们将以此次上市为契机,继续深耕创新疫苗领域,...
Source Link8月11日,江苏中慧元通生物科技股份有限公司(简称“中慧生物”,股票代码:2627.HK)正式在中国香港联交所主板挂牌上市,开盘即大涨156%。公司核心产品之一四价流感病毒亚单位疫苗(慧尔康欣®)是国内首款且截至目前唯一获批的四价流感病毒亚单位疫苗。中慧生物成为高特佳投资又一IPO项目。中慧生物董事长、总经理安有才表示:“上市不是终点,而是新的起点。我们将以此次上市为契机,继续深耕创新疫苗领域,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.